ClinicalTrials.Veeva

Menu
J

Johnson County Clin-Trials | Lenexa, KY

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

TDV
Atropine
Sodium chloride
mRNA-1345
sodium chloride
Zirconium Silicate

Parent organization

This site is a part of Johnson County Clin-Trials

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

19 of 82 total trials

A Long-Term Extension Study to Evaluate the Immunogenicity and Safety of Cytomegalovirus (CMV) mRNA-1647 Vaccine

The main purpose of the extension phase of this study is to evaluate the longer-term immune persistence of mRNA-1647 vaccine administered to CMV-sero...

Invitation-only
Cytomegalovirus Infection
Other: mRNA-1647

The main objective of Part A of this trial is to evaluate the safety and reactogenicity of mRNA-1189 in 18- to 30-year-old healthy adults, the main o...

Enrolling
Epstein-Barr Virus Infection
Biological: mRNA-1189
Biological: Placebo

The purpose of this study is to evaluate the safety and reactogenicity of mRNA-1195 in healthy adults (18 to 55 years of age).

Active, not recruiting
Epstein-Barr Virus Infection
Biological: Placebo
Biological: mRNA-1195.2

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1010, and to evaluate relative vaccine efficacy (rVE) of m...

Enrolling
Seasonal Influenza
Biological: Fluarix®
Biological: Influsplit®

The purpose of this study (Part 1 and Part 2) is to evaluate the relative vaccine efficacy (rVE), safety, reactogenicity, and immunogenicity of mRNA-...

Active, not recruiting
COVID-19
Biological: mRNA-1283.222
Biological: mRNA-1273.815

The purpose of this study is to generate safety and immunogenicity data and establish a proof-of-concept of clinical benefit of the mRNA-1608 vaccine...

Active, not recruiting
Genital Herpes
Biological: BEXSERO
Biological: mRNA-1608

The study is divided into 2 parts: Part 1 and Part 2. The purpose of Part 1 of this study is to generate sufficient safety, reactogenicity, and immun...

Active, not recruiting
Influenza
SARS-CoV-2
Biological: Investigational Influenza Vaccine 1
Biological: COVID-19 Vaccine 2

The purpose of this study is to assess the safety, reactogenicity, and immunogenicity of 3 different doses of ExPEC10V and to select the optimal dose...

Active, not recruiting
Extraintestinal Pathogenic Escherichia Coli Prevention
Biological: ExPEC10V
Biological: ExPEC4V

This study is designed to evaluate the safety and immunogenicity of two monovalent Norovirus (NoV) oral tableted vaccine candidates, VXA-G1.1-NN and...

Active, not recruiting
Norovirus Infections
Drug: Placebo
Drug: Bivalent GII.4/GI.1 medium dose vaccine 1×10 to the power 11 IU/dose

The main purpose of Part A of this study is to evaluate the safety and tolerability of mRNA-1345 vaccine and to demonstrate the efficacy of a single...

Active, not recruiting
Respiratory Syncytial Virus
Drug: Placebo
Drug: mRNA-1345

The purpose of this study is to evaluate the safety and immunogenicity in parallel of heptavalent mRNA-1975 and monovalent mRNA-1982 against Lyme dis...

Active, not recruiting
Lyme Disease
Biological: Placebo
Biological: mRNA-1975

The purpose of this first-in-human study is to evaluate the safety and immunogenicity of mRNA-1468.

Active, not recruiting
Herpes Zoster
Biological: Shingrix
Biological: Placebo

The primary objective of the study is to determine the relative efficacy of the investigational oral severe acute respiratory syndrome coronavirus 2...

Enrolling
COVID-19
SARS-CoV2
Biological: VXA-CoV2-3.1
Biological: COMIRNATY®

The primary objectives of this study are to evaluate the safety and reactogenicity of mRNA-1403, and to demonstrate the efficacy of mRNA-1403 to prev...

Enrolling
Acute Gastroenteritis
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

This BARDA-sponsored, randomized, double-blind, phase 2 study is designed to assess safety and immunogenicity of A/H5 inactivated monovalent influenz...

Active, not recruiting
Influenza
Biological: 3.75 µg H5N8 antigen plus full dose AS03A
Biological: 7.5 µg H5N8 antigen plus half dose AS03A

This is an exploratory Phase I, randomized, observer-blind, active-controlled, dose-escalation trial to evaluate four dose levels (DLs) of BNT162b4 g...

Active, not recruiting
COVID-19
SARS-CoV-2 Infection
Biological: BNT162b4 10 µg
Biological: BNT162b4 15 µg

This study evaluates an investigational vaccine that is designed to protect humans against infection with SARS-CoV-2, the novel coronavirus causing C...

Enrolling
Covid19
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 3, Single Dose, Intranasal Drops
Biological: Investigational vaccine against SARS-CoV-2 [MV-014-212] Dosage 2, Single Dose, Intranasal Drops

The purpose of this study is to select a dose of CD388 that is effective in preventing symptomatic laboratory-confirmed influenza infections, as comp...

Active, not recruiting
Influenza
Combination Product: CD388 Injection
Combination Product: Placebo

The purpose of the Phase 1 Part of this study is to evaluate the safety, reactogenicity, and immunogenicity of mRNA-1403 and mRNA-1405 in healthy adu...

Active, not recruiting
Norovirus Acute Gastroenteritis
Biological: mRNA-1403
Biological: Placebo

Trial sponsors

Moderna logo
Bavarian Nordic logo
B
Novavax logo
Janssen (J&J Innovative Medicine) logo
Takeda logo
V
A
M
N

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems